4-(3-Fluoro-4-methoxyphenyl)-4-methyl-5,6-dihydro-1,3-thiazin-2-amine | 935990-57-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 4-(3-Fluoro-4-methoxyphenyl)-4-methyl-5,6-dihydro-1,3-thiazin-2-amine
• CAS: 935990-57-1
• 化学式: C₁₂H₁₅FN₂OS
• 分子量: 254.328
• InChiKey: LXVHTUSIBOTEQE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  72.9
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-(3-Fluoro-4-methoxyphenyl)-4-methyl-5,6-dihydro-1,3-thiazin-2-amine 、 N,N'-di-t-butoxycarbonyl-3,5-dimetylpyrazolyl-1-carboxamidine 以 乙腈 为溶剂， 反应 25.0h， 生成 tert-butyl N-[N'-[4-(3-fluoro-4-methoxyphenyl)-4-methyl-5,6-dihydro-1,3-thiazin-2-yl]-N-[(2-methylpropan-2-yl)oxycarbonyl]carbamimidoyl]carbamate
  参考文献：
  名称：

  AMINODIHYDROTHIAZINE DERIVATIVE

  摘要：

  公开号：

  EP1942105B1

文献信息

• AMINODIHYDROTHIAZINE DERIVATIVE
  申请人：Shionogi Co., Ltd.

  公开号：EP1942105B1

  公开（公告）日：2014-04-16
• Aminothiazolidine and aminotetrahydrothiazepine derivatives as BACE 1 inhibitors
  申请人：Shionogi & Co., Ltd.

  公开号：EP2612854B1

  公开（公告）日：2015-04-29
• Dihydrooxazine and tetrahydropyrimidine derivatives as BACE 1 inhibitors
  申请人：Shionogi & Co., Ltd.

  公开号：EP2597087B1

  公开（公告）日：2016-03-30
• AMINODIHYDROTHIAZINE DERIVATIVES
  申请人：Kobayashi Naotake

  公开号：US20090082560A1

  公开（公告）日：2009-03-26

  A composition having BACE 1 inhibitory activity containing a compound represented by the general formula (I): wherein ring A is an optionally substituted carbocyclic group or an optionally substituted heterocyclic group; E is lower alkylene; X is S, O, or NR 1 ; R 1 is a hydrogen atom or lower alkyl; R 2a , R 2b , R 3a , R 3b , R 4a and R 4b is each independently a hydrogen atom, halogen, or hydroxy etc.; n and m are each independently an integer of 0 to 3; n+m is an integer of 0 to 3; R 5 is a hydrogen atom or substituted lower alkyl; its pharmaceutically acceptable salt, or a solvate thereof.
• PHARMACEUTICAL COMPOSITION FOR TREATING ALZHEIMER'S DISEASE
  申请人：Kobayashi Naotake

  公开号：US20100160290A1

  公开（公告）日：2010-06-24

  A pharmaceutical composition for treating Alzheimer's disease containing a compound represented by the general formula (I); wherein ring A is an optionally substituted carbocyclic group or an optionally substituted heterocyclic group; E is lower alkylene, etc.; X is S, O, or NR 1 ; R 1 is a hydrogen atom or lower alkyl; R 2a , R 2b , R 3a , R 3b , R 4a and R 4b are each independently a hydrogen atom, halogen, hydroxy, etc.; n and m are each independently an integer of 0 to 3; n+m is an integer of 1 to 3; and R 5 is a hydrogen atom, optionally substituted lower alkyl, etc.; its pharmaceutically acceptable salt, or a solvate thereof as an active ingredient.